Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pilot RCT of a Chinese Medicine Diabetes Education Programme

6. August 2026 aktualisiert von: HO Janice Yuen-Shan, The Hong Kong Polytechnic University

Development and Pilot Test of a Chinese Medicine Diabetes Education Program 中醫糖尿病個人管理教育方案建構及初步試驗

The goal of this clinical trial is to learn if a Chinese medicine diabetes education programme is feasible and acceptable, and to explore its preliminary effects on self-management, for adults with type 2 diabetes in Hong Kong. The main questions it aims to answer are:

  1. Is the Chinese medicine diabetes education programme feasible to deliver in a community setting (recruitment, retention and adherence)?
  2. Is the programme acceptable to participants?
  3. Does the programme show early signals of improving diabetes management self-efficacy and related outcomes?

Researchers will compare the Chinese medicine education programme to usual care to see if the programme is feasible, acceptable and shows preliminary benefits.

Participants will:

  1. Be randomly assigned to either a 4-week Chinese medicine diabetes education programme (four group sessions, total 4-6 hours) or usual care
  2. Complete assessments at baseline, after the programme, and at 2-month follow-up.
  3. Attend a focus group interview at the end of the study (selected participants)

Outcome assessors will be blinded to group allocation.

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

This pilot randomised controlled trial evaluates the feasibility, acceptability and preliminary effects of a Chinese medicine diabetes education programme for adults with type 2 diabetes in Hong Kong.

While Western-medicine-based diabetes education is well established locally, systematic and interactive Chinese medicine education remains limited. The programme integrates Chinese medicine concepts (body constitution, pattern differentiation, dietary therapy, emotional regulation, acupressure and lifestyle advice) with modern self-management principles. Content was refined through literature review, patient input and Delphi consensus.

Forty adults with type 2 diabetes will be randomly allocated (1:1) to either a 4-week group education programme (four sessions, total 4-6 hours) or usual care. The control group will be offered the programme after final follow-up. Participants and facilitators are not blinded due to the nature of the educational intervention; outcome assessors will remain blinded to group allocation.

Primary aims are to assess feasibility (recruitment, retention, adherence) and acceptability. Exploratory outcomes, measured at baseline, post-intervention and 2-month follow-up, include diabetes management self-efficacy (Chinese version of the Diabetes Management Self-Efficacy Scale, C-DMSES; Wu et al., 2008), self-management behaviours, blood glucose, lipids, BMI and blood pressure. Focus group interviews will gather qualitative feedback.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Adults aged 18 years or above
  • Diagnosed with type 2 diabetes mellitus
  • Able to understand and communicate in Cantonese, and able to read Chinese
  • Willing and able to provide written informed consent
  • Able to attend the education sessions at the designated venues

Exclusion Criteria:

  • Severe cognitive impairment that would prevent meaningful participation in group education
  • Acute or unstable medical conditions, or serious chronic illnesses currently under active treatment (e.g., ongoing cancer treatment), that may preclude safe participation in group activities
  • Currently participating in another structured diabetes education research programme
  • Pregnancy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Usual Care
Participants will continue their usual medical care and any existing diabetes education or support. No additional structured Chinese medicine diabetes education programme will be provided during the study. After the final follow-up, they will be offered the same education programme.
Experimental: Chinese Medicine Diabetes Education Programme
Participants will receive a 4-week Chinese medicine diabetes education programme consisting of four weekly group sessions (total 4-6 hours). Content includes Chinese medicine concepts of diabetes, body constitution, diet, emotional regulation, acupressure, skin and foot care, and physical activity.
A structured 4-week group education programme (four sessions, total contact time 4-6 hours) that integrates Chinese medicine concepts (body constitution, pattern differentiation, dietary therapy, emotional regulation, acupressure, and lifestyle advice) with modern diabetes self-management education.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recruitment rate
Zeitfenster: From start of recruitment to end of recruitment period
Proportion of eligible individuals who provide informed consent and are randomised into the study.
From start of recruitment to end of recruitment period
Retention rate
Zeitfenster: From randomisation to 2-month follow-up
Proportion of randomised participants who complete the post-intervention assessment (T1) and the 2-month follow-up assessment (T2).
From randomisation to 2-month follow-up
Adherence to the education programme
Zeitfenster: During the 4-week intervention period
Proportion of participants in the intervention group who attend at least 3 out of the 4 scheduled education sessions.
During the 4-week intervention period
Acceptability of the programme
Zeitfenster: At the end of the 4-week education programme
Participant-reported acceptability and satisfaction with the Chinese medicine diabetes education programme, assessed by a structured questionnaire at the end of the programme. Additional qualitative feedback will be collected through focus group interviews at 2-month follow-up.
At the end of the 4-week education programme

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Diabetes management self-efficacy
Zeitfenster: Baseline, post-intervention (T1), and 2-month follow-up (T2)
Measured by the Chinese version of the Diabetes Management Self-Efficacy Scale (C-DMSES).
Baseline, post-intervention (T1), and 2-month follow-up (T2)
Diabetes self-management behaviours
Zeitfenster: Baseline, post-intervention (T1), and 2-month follow-up (T2)
Self-reported diabetes self-management behaviours, assessed using a participant logbook recording the frequency of exercise, acupressure, blood glucose monitoring and other self-care activities.
Baseline, post-intervention (T1), and 2-month follow-up (T2)
Blood glucose level
Zeitfenster: Baseline and 2-month follow-up (T2)
Fasting blood glucose level, HbA1c
Baseline and 2-month follow-up (T2)
Blood lipid levels
Zeitfenster: Baseline and 2-month follow-up (T2)
Total cholesterol, triglycerides, HDL-C and LDL-C
Baseline and 2-month follow-up (T2)
Body mass index (BMI)
Zeitfenster: Baseline, post-intervention (T1), and 2-month follow-up (T2)
Calculated from measured height and weight.
Baseline, post-intervention (T1), and 2-month follow-up (T2)
Blood pressure
Zeitfenster: Baseline, post-intervention (T1), and 2-month follow-up (T2)
Systolic and diastolic blood pressure.
Baseline, post-intervention (T1), and 2-month follow-up (T2)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Yuen-Shan Ho, PhD, The Hong Kong Polytechnic University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. Juli 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

28. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

6. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. August 2026

Zuerst gepostet (Tatsächlich)

11. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. August 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren